ClinicalTrials.gg
RecruitingNCT06900920Updated May 20, 2025

A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia

A Phase 3 interventional study of TQB3473 Tablets and TQB3473 Placebo in Primary Immune Thrombocytopenia, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 53 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 82 open to participants now, 92 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
21st of 167
199 · median 62
Started
2025
with 26 others
Phase 3
39 of 185
7 open now
Primary completion
2027-03
later than 55 of 91 live
Registered
148th of 185
by date

Among the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 21st largest by planned enrollment of the 167 interventional ones that give a count, is one of 27 that started in 2025, is one of 39 in phase 3, reaches primary completion later than 55 of the 91 other live ones, and was the 148th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

82 of the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled Phase III clinical study designed to demonstrate that TQB3473 tablets significantly improve the sustained response rate compared to placebo in adult patients with chronic ITP who have previously received standard corticosteroid therapy and have failed or relapsed after at least one standard ITP treatment.

The study consists of a treatment period and a safety follow-up period.

03

Conditions studied

  • Primary Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily join this study, sign the form (ICF), and demonstrate good compliance;
  • Male or female subjects aged 18 to 75 years (calculated based on the date of signing the informed consent form);
  • (ECOG) score of 0-1;
  • Diagnosis of primary ITP prior to randomization, with a duration of ≥12 months;
  • An average of at least three independent counts (spaced more than 3 days apart) within the 3 months prior to randomization \<30×10\^9/L, with no count >35×10\^9/L; and no severe bleeding within 4 weeks prior to screening;
  • Previous treatment with and at least one standard ITP therapy that was ineffective or resulted in relapse.
  • Female subjects of must agree to use effective during the study and for 6 months after the end of study treatment, with a negative serum or urine pregnancy test within 7 days prior to study enrollment; male subjects must agree to use effective contraception during the study and for 6 months after the end of study treatment, as detailed in Section 5.5.

Exclusion criteria

Exclusion Criteria:

  • Evidence of secondary causes of ITP (e.g., untreated Helicobacter pylori infection, leukemia, lymphoma, history of diseases such as systemic lupus erythematosus, Hashimoto's thyroiditis, etc.) or drug-induced causes (e.g., anticonvulsants, antibiotics, heparin, etc.), or immune-mediated cytopenia involving two or more cell lines such as Evans syndrome or immune-related cytopenia;
  • Subjects with a history or current diagnosis of myelofibrosis, myelodysplastic syndrome, aplastic anemia, lymphoproliferative disorders, or other malignant hematologic diseases;
  • History of or concurrent other within the past 3 years. Exceptions include: other malignancies treated with a single surgical procedure and achieving continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)];
  • Conditions affecting venous blood sampling or multiple factors affecting oral medication (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.);
  • Adverse reactions from previous treatments have not resolved to ≤ grade 1, except for non- and asymptomatic laboratory abnormalities judged by the investigator to pose no safety risks;
  • Previous bone marrow/hematopoietic stem cell transplantation or major solid organ transplantation;
  • Vaccination within 8 weeks prior to randomization or planned vaccination during the study period;
  • Major surgical treatment or significant traumatic injury within 4 weeks prior to randomization, or anticipated need for major elective surgery during the study treatment period (major surgery is defined as level 3 or higher according to the National Surgical Classification Catalog 2022);
  • History of intracranial hemorrhage or other severe bleeding in vital organs (≥CTCAE grade 3), or symptomatic gastrointestinal bleeding (e.g., hematemesis, melena, etc., excluding asymptomatic "occult blood test positive" and hemorrhoids) within 6 months prior to screening;
  • Arterial/venous thrombotic events within 12 months prior to randomization, such as cerebrovascular accidents (including ), deep vein thrombosis, or pulmonary embolism;
  • ITP-related symptoms and treatments:

    1. Receipt of immunoglobulins or transfusions within 2 weeks prior to randomization;
    2. Receipt of treatments aimed at increasing platelet counts (including but not limited to , Thyroid peroxidase (TPO), Thrombopoietin receptor agonists (TPO-RAs), cyclosporine, herbal medicines, etc.) within 4 weeks prior to randomization, except for those meeting inclusion criterion (8);
    3. Use of rituximab or other anti-cluster of differentiation 20 (CD20) drugs within 14 weeks prior to randomization;
    4. Splenectomy within 12 weeks prior to randomization.
  • Need for long-term/continuous use of medications affecting platelet function [including but not limited to aspirin, clopidogrel, ticagrelor, non-steroidal anti-inflammatory drugs (NSAIDs), etc.] or anticoagulant therapy;
  • Known allergy to the active ingredient or of the drug;
  • Previous treatment with Syk inhibitors;
  • Participation in another clinical trial and use of investigational drugs within 4 weeks prior to randomization;
  • Any condition judged by the investigator to pose a significant risk to the subject's safety or to affect the subject's ability to complete the study.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
199 participants (estimated)

Study arms

  • Active comparator
    TQB3473 Tablets

    TQB3473 Tablets 600 mg orally once daily for 24 consecutive weeks.

    Drug: TQB3473 Tablets

  • Placebo comparator
    TQB3473 Placebo

    Placebo, orally once daily for 24 consecutive weeks.

    Drug: TQB3473 Placebo

Interventions

  • TQB3473 tablet is a selective Spleen tyrosine kinase (Syk) inhibitor.

  • DrugTQB3473 Placebo

    Placebo contains no active substance.

06

What researchers measure

Primary outcomes

  1. Durable response rate: platelet counts ≥50×10^9/L

    During the 24-week randomized double-blind treatment period (Weeks 14-24), platelet counts ≥50×10\^9/L in at least 4 out of the 6 protocol-specified visits (excluding rescue treatment).

    Time frame: During the 24-week randomized double-blind treatment period (Weeks 14-24)

Secondary outcomes

  1. The effectiveness rate within the first 12 weeks of treatment

    ①The proportion of subjects with at least one platelet count ≥50×10\^9/L during weeks 1-12 (excluding emergency treatment).②Among subjects with a baseline platelet count \<15×10\^9/L, the proportion of subjects with at least one platelet count ≥30×10\^9/L and an increase of ≥20×10\^9/L from baseline during weeks 1-12 (excluding rescue treatment).

    Time frame: Baseline to 12 weeks

  2. The response rate within 24 weeks of treatment

    ① The proportion of subjects with at least one platelet count ≥50×10\^9/L during weeks 1-24 (excluding rescue treatment). ② Among subjects with a baseline platelet count \<15×10\^9/L, the proportion of subjects with at least one platelet count ≥30×10\^9/L and an increase of ≥20×10\^9/L from baseline during weeks 1-24 (excluding rescue treatment). ③ The proportion of subjects with platelet counts at least twice the baseline level and ≥30×10\^9/L for at least two consecutive measurements during weeks 1-24 (excluding rescue treatment).

    Time frame: 24 weeks

  3. Time to response: The time from the initiation of treatment to the first platelet count ≥50×10^9/L

    The time from the initiation of treatment to the first platelet count ≥50×10\^9/L

    Time frame: The time from the initiation of treatment to the first platelet count ≥50×10^9/L (excluding rescue treatment)

  4. The incidence and severity of bleeding events (Weeks 1-12)

    During Weeks 1-12 of the double-blind treatment period, the incidence and severity of bleeding events as assessed by the World Health Organization (WHO) bleeding score.

    Time frame: During Weeks 1-12 of the double-blind treatment period

  5. The incidence and severity of bleeding events (Weeks 1-24)

    During Weeks 1-24 of the double-blind treatment period, the incidence and severity of bleeding events as assessed by the World Health Organization (WHO) bleeding score.

    Time frame: During Weeks 1-24 of the double-blind treatment period

  6. The proportion of subjects who receive rescue treatment

    The proportion of subjects who receive rescue treatment aimed to increase platelet counts during the 24-week double-blind treatment period.

    Time frame: During the 24-week double-blind treatment period

  7. The change of concomitant therapy

    The proportion of subjects who reduce or discontinue concomitant ITP treatments during the 24-week double-blind treatment period.

    Time frame: During the 24-week double-blind treatment period

  8. The incidence and severity of adverse events

    The proportion of subjects experiencing adverse events and the severity of these events, with adverse events assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From the signing of the informed consent until 28 days after the last dose of study drug or the initiation of new ITP treatment, whichever occurs first

07

Study locations

1 of 53 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's planned 23 months is close to that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 28, 2025
StartActual
Apr 30, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Dec 2027
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06900920
Responsible party
Sponsor
First posted
Mar 28, 2025
Start date
Apr 30, 2025
Primary completion
Mar 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 20, 2025

Study contacts

Hu Zhou, Doctor
Contact
papertigerhu@163.com
13939068863

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQB3473

Start the discussion